Impact of HCV Ns5a Resistance Associated Substitutions on Treatment Outcome of Chronic HCV in Daclatasvir-Based Antiviral Regimens

Background: RASs have direct relation to the treatment outcome in chronic HCV patients receiving DAAs. Aim and objectives: to evaluate prevalence of NS5A HCV RASs and their impact on the treatment outcome in daclatasvir-based antiviral regimens in a cohort of Egyptian patients. Subjects and methods: This study was conducted on 40 Egyptian chronic HCV patients at the virology unit of Cairo Fatemya hospital. The study participants were recruited from cases attending the virology unit of Cairo Fatemya hospital in the period from 1/11/2019 to 1/6/2020. Those patients were divided to two equal groups: responders and non responders (20 patient each).Result:Significant difference was found between the two groups as regard RAS in NS5A region in amino acid position 332 (K substitution was detected in responders while E substitution was detected in non-responders), There was a significant difference between the two groups of studied patients as regard RAS in NS5A region in amino acid position 28 (L substitution was found in responders while M substitution was found in non-responders).Conclusion; Although our results showed that RASs against NS5A and NS5B inhibitors have impact on treatment outcome, this finding needs to be confirmed by a larger study.